article thumbnail

Scrub-a-Dub-Dub: FTC is Cleansing the Orange Book of Device Patents

FDA Law Blog: Biosimilars

Koblitz — As we have noted for the last year or so, the FTC has been on a mission to clean up the Orange Book by removing what it deems to be “improper” patents. FTC, deep in its foray into the Orange Book, filed an Amicus Brief in the case arguing that the patents do not claim any FDA-approved drug. And on X (R.I.P.

Dosage 113
article thumbnail

FTC Continues to Rage Against Device Patent Listings in the Orange Book

FDA Law Blog: Biosimilars

Koblitz — The FTC appears to be on a mission to cleanse the Orange Book of patents it deems improperly listed. For the second time in recent years, the FTC has filed an Amicus Brief explaining exactly which patents should not be in the Orange Book. Because a “drug product” is defined by regulation as a “Finished dosage form.

Dosage 57
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Episode 575: Novel dosage forms that should not be crushed (but look like they can be)

Pharmacy Joe

In this episode, I’ll discuss novel dosage forms that should not be crushed but look like they can be. Episode 575: Novel dosage forms that should not be crushed (but look like they can be) Subscribe on iTunes , Android , or Stitcher Two relatively new dosage form technologies are nanocrystals and amorphous solid dispersions.

Dosage 40
article thumbnail

Episode 864: Why Did ISMP Remove the Do Not Crush List from Their Website?

Pharmacy Joe

Subscribe on iTunes , Android , or Stitcher If you navigate to the page on the website for the Institute for Safe Medication Practices that once hosted the document titled “Oral Dosage Forms That Should Not Be Crushed” you will instead find a notice that the list has been removed from the ISMP website.

Dosage 111
article thumbnail

To List or Not to List; That is the Question – The FTC Signals the Potential for Greater Scrutiny of Patent Information Submissions to FDA

FDA Law Blog: Biosimilars

Karst — Listing patent information in the Orange Book is a matter of judgment, but that judgment call is about to get a bit more scrutiny. Last week, the FTC held a Listening Session about the listing of patents in the Orange Book, which concluded with a unanimous vote to issue a Policy Statement.

article thumbnail

Drugs Companies Clap Back at Congress…Then Get Sued

FDA Law Blog: Biosimilars

Koblitz — After years of silence from FDA on whether certain patents could be listed in the Orange Book, some manufacturers of drug and device combination products have had a rude awakening lately. Rather, the FTC questioned whether these patents meet the statutory and regulatory criteria for listing in the Orange Book.

Dosage 57
article thumbnail

Drug Formulary App

RX Note

It is a quick reference for indication, dosage, availability and prescribing category. Blue Book + CPG Malaysia under Ice Cream App Database last updated to MOHMF 2022-1. Introduction If you are working at government healthcare facilities at Malaysia, you must have referred Ministry of Health Medicines Formulary (MOHMF) before.